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We used multiple regression models to assess the inﬂu-
ence of disease stage at diagnosis on the 5-year relative
survival of 4,478 patients diagnosed with breast cancer in
1990–1992. The cases were representative samples from 17
population-based cancer registries in 6 European countries
(Estonia, France, Italy, Netherlands, Spain and UK) that were
combined into 9 regional groups based on similar survival.
Five-year relative survival was 79% overall, varying from 98%
for early, node-negative (T1N0M0) tumours; 87% for large,
node-negative (T2-3N0M0) tumours; 76% for node-positive
(T1-3NM0) tumours and 55% for locally advanced
(T4NxM0) tumours to 18% for metastatic (M1) tumours and
69% for tumours of unspeciﬁed stage. There was consider-
able variation across Europe in relative survival within each
disease stage, but this was least marked for early node-
negative tumours. Overall 5-year relative survival was high-
est in the French group of Bas-Rhin, Coˆte d’Or, He´rault and
Ise`re (86%), and lowest in Estonia (66%). These geographic
groups were characterised by the highest and lowest per-
centages of women with early stage disease (T1N0M0: 39%
and 9%, respectively). The French, Dutch and Italian groups
had the highest percentage of operated cases. The number of
axillary nodes examined, a factor inﬂuencing nodal status,
was highest in Italy and Spain. After adjusting for TNM stage
and the number of nodes examined, survival differences were
greatly reduced, indicating that for these women, diagnosed
with breast cancer in Europe during 1990–1992, the survival
differences were mainly due to differences in stage at diag-
nosis. However, in 3 regional groups, the relative risks of
death remained high even after these adjustments, suggest-
ing less than optimal treatment. Screening for breast cancer
did not seem to affect the survival patterns once stage had
been taken into account.
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The EUROCARE study of the survival and care of cancer
patients in Europe has shown marked variations in survival from
breast cancer,1,2 with highest survival in Nordic countries (Swe-
den, Finland, Iceland and Norway) and lowest survival in the
countries of the former Eastern bloc. Low survival was also found
in the UK and Denmark. These survival differences are not easily
interpreted. Longer survival could be due to better treatment, more
effective treatment due to diagnosis at earlier stage or simply to
early diagnosis without any advantage to the patient (lead-time
bias). In a previous study designed to explain these regional
differences, we analysed detailed diagnostic and therapeutic infor-
mation on samples of breast cancer patients diagnosed in 1990–
1991 who were recorded in cancer registry ﬁles. We found differ-
ences between the cancer registry areas in stage at diagnosis that
were related to the overall survival differences.3
Regional survival differences should therefore diminish if ap-
propriate stage-adjusted comparisons are performed. However,
stage is highly sensitive to the diagnostic procedures used to deﬁne
it, and the thoroughness of the investigations performed, particu-
larly those capable of revealing occult metastases.4 As a conse-
quence, tumours classiﬁed as “localised” in an area where inten-
sive diagnostic investigations are usually performed are likely to
be more localised than tumours assigned the same stage in another
area where investigations are (for whatever reason) less thorough.
The corollary is that the survival of “localised” cases will be better
in the area of intensive investigation, simply because of a different
de facto deﬁnition of stage at diagnosis, and not because of better
treatment. Furthermore, “advanced” cases will also have better
survival in the area of intensive investigation because of the
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inclusion of some less advanced metastatic cases in this category
that would be classiﬁed as “localised” in the area of less thorough
investigation.5 Stage-adjusted survival comparisons should, there-
fore, take into account the diagnostic examinations used to deﬁne
the stage.
The aim of our study is to present stage-speciﬁc 5-year relative
survival for breast cancer from selected European cancer registries,
and to analyse the effects of disease stage at diagnosis, age, general
mortality and the number of nodes examined during lymphade-
nectomy using a multivariate regression model to assess the inﬂu-
ence of all these factors on survival. The number of axillary lymph
nodes examined pathologically was 1 of the most important de-
terminants of breast cancer stage during the early 1990s.
The results should make it possible to interpret the differences in
breast cancer survival across Europe. Survival differences that
persist after adjustment for tumour stage at diagnosis are more
likely to be due to differences in treatment or to differences in
tumour biology. We have performed a similar analysis of the
survival of colon cancer patients in Europe.6
MATERIAL AND METHODS
Seventeen population-based cancer registries from 6 European
countries (Estonia, France, Italy, Netherlands, Spain and UK)
participating in EUROCARE adhered to a common protocol for
investigating the diagnostic and therapeutic procedures used for
treating breast cancer. Each registry provided a representative
sample of breast cancer cases diagnosed in 1990 (1991 for Estonia
and Netherlands) or during the period 1990–1992 for the smallest
cancer registry (Ragusa, Southern Italy). Detailed clinical infor-
mation on each case was subsequently abstracted from the clinical
notes by trained personnel.
The participating cancer registries were asked to provide data on
all cases of invasive breast cancer, or a representative sample
thereof, diagnosed in 1990. At least 200 cases per registry were
required; if this minimum was not reached in 1990, the study
period was prolonged until 200 cases were accrued. A total of
4,478 breast cancer cases were analysed. Data collection was
considered complete when, for each registry, the number of cases
collected by the trained personnel was equal to the total number of
incident cases in the registry records. Extensive details of the study
design and inclusion criteria are included in the ﬁrst descriptive
analysis.3
Most of the clinical items requested were available in the
primary treatment clinical records. However, in some registries,
extent of disease at diagnosis was not available for many cases and
had to be reconstructed by examining other clinical records in
addition (e.g., pathology reports and discharge records).
Extent of disease at diagnosis was categorized according to
TNM rules (3rd edition).7 Pathologic T and N categories were used
for women who underwent surgery, and clinical information on T,
N and M was used for those not treated surgically. We present the
cancer registry data by country and, within France, Italy and the
UK, for groups of 1 or more regional registries deﬁned by similar
survival and stage distribution at diagnosis. Thus, for Italy, the
registries of Varese, Firenze and Modena, in the northern part of
the country, were grouped together; while Ragusa in south-eastern
Sicily was kept separate. Two groups with similar survival were
identiﬁed in France, the ﬁrst comprising the registries of Bas-Rhin,
Coˆte d’Or, He´rault and Ise`re; the second those of Tarn, Somme,
Calvados and Doubs. In the UK, the registries of Thames and
Mersey were kept separate, as they differed considerably in the
distribution of stage at diagnosis and in breast cancer survival.
Each individual registry used its own follow-up procedures. The
UK registries updated the life status of patients included in our
study, linking death certiﬁcates of the general population to the
registry records; all the other registries performed an active search
of the life status of their patients using various sources of infor-
mation (e.g., registry of general practitioners, municipality ﬁles).
At least 5 years’ follow-up information was available for all
women. For patients included in the ﬁrst EUROCARE study,
diagnosed in 1978–1985, we performed an extensive follow-up
quality study of long-surviving cases in registries that employed
passive follow-up procedures. We found that the small number of
errors uncovered in terms of life status did not affect survival
estimates.4 Comparison of registry-speciﬁc 5-year relative survival
of cases included in our study with that of the Eurocare-2 project,
including patients diagnosed in 1985–1989, revealed satisfactorily
consistent survival levels, indicating that the quality of follow-up
for the patients in the present study was high.3
Relative survival, expressing the probability of cancer survival
after adjustment for competing causes of death, was estimated as
the ratio of the observed survival to the expected survival based on
the age- and sex-speciﬁc mortality rates of the general population
from which the cancer cases were drawn. Overall and stage-
speciﬁc 5-year relative survival rates were calculated by the Haku-
linen method8 using general population life tables speciﬁc for each
registry region.
For the univariate analysis, stage was assigned to 1 of 5 categories:
small, node-negative (T1N0M0); large, node-negative (T2-3N0M0);
node-positive (T1-3NM0, regardless of the number and anatomic
level of the involved nodes in the axilla); locally advanced (T4NxM0,
large tumours with skin/chest wall involvement, regardless of nodal
status); metastatic (M1) and of unspeciﬁed stage.
Geographic differences in 5-year relative survival were mod-
elled using a recently developed multiple regression approach
based on generalised linear models and adopting the Poisson
assumption for the observed number of deaths.9 The relative
excess risks (RERs) derived from these models quantify the extent
to which the hazard of death in a given area (age group, etc.)
differs from the hazard in the reference category after taking into
account the overall risk of death in the general population.
In these models, age at diagnosis was categorized into 40 years,
40–49, 50–69 and 70 years or more (reference category) because
these age ranges correspond to different hormone patterns associated
with different prognosis, and because screening for breast cancer is
usually carried out after age 50. Surgical treatment of the breast was
included in the model regardless of the type of surgery.
The 3 components of disease stage, T, N and M, were modelled
separately to estimate the independent prognostic value of each,
adjusted for all the other factors included in the analysis. Tumour
size was divided into 4 categories (T1–T4, according to TNM
rules), with T1 as reference. Nodal status was categorised by the
number of metastatic nodes, divided into 10 categories, with no
positive nodes (N0) as the reference group, and additional catego-
ries for clinically node-negative cases, nodal metastases with an
unknown number of involved nodes and nodal status unknown.
The number of metastatic nodes was chosen as an indicator of
nodal stage because it is itself a prognostic indicator,10–12 and
because the number of metastatic nodes was more widely available
in participating cancer registries than the standard N categories
based on TNM rules. The probability of detecting nodal metastases
is directly related to the number of axillary nodes examined
pathologically. The number of lymph nodes examined was there-
fore also included in the models as a determinant of nodal status,
categorised into tertiles, with a fourth category for cases where the
axilla was not examined surgically; a few cases for which this
information was not available were grouped with the last category.
RESULTS
Table I shows the total number of cases by country and regional
group, with information on treatment, stage and staging procedures
inﬂuencing N stage. More detailed information on stage at diag-
nosis and treatment of these patients has been published.3
During the study period, organised breast cancer screening was in
place in the UK and in the French regions of Bas-Rhin, He´rault and
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Ise`re. In Florence (Italy) and Eindhoven (Netherlands), screening
programmes started soon after the period of eligibility for our study.13
Most patients (90%; range 75–93%) were treated surgically; the
lowest percentages were those for Estonia (75%) and Thames
(UK) (83%). Mersey (UK), Granada (Spain) and Ragusa (Italy)
also had low percentages of surgery (all 88%).
Axillary dissection was performed most often in the Italian and
French registry areas (80–90% of cases), and in Eindhoven (Neth-
erlands: 87%). Ten or more lymph nodes were examined in 59%
of cases overall, with the highest proportions in Granada (Spain)
and Italy (71–83%), and the lowest in Estonia (only 3%). In the
UK, only 50% of women underwent axillary lymphadenectomy,
and the number of nodes examined was low.
Overall, 2.9% of patients were lost to follow-up, ranging from
1% or less (Italy, Netherlands, UK) to 5–6% in France.
Early, node-negative cancers accounted for 29% of all cases
(Table II), ranging from 8.5% in Estonia to 39.4% in France
(Bas-Rhin, Coˆte d’Or, He´rault and Ise`re). In 8.5% of cases overall,
the stage at diagnosis was unknown or could not be reconstructed
from available clinical notes, with the highest percentage in
Thames (31%).
Relative survival varied widely between these European popu-
lations, as has been reported in previous EUROCARE studies.1,2
Five-year survival ranged from 66% in Estonia to 86% in the
French regional group of Bas-Rhin, Coˆte d’Or, He´rault and Ise`re
(Table II). Survival was generally related to stage distribution, in
that areas with a higher proportion of breast cancers diagnosed at
earlier stages had better overall survival. In all areas, survival
decreased markedly with advancing stage.
Survival within a given category of stage also varied between
geographic regions, especially for the more advanced stage
categories (Table II). Thus 5-year relative survival for the
combined group of women with tumours conﬁned to the breast
(T1N0M0 and T2-3N0M0) was 90% or higher for all registries
except Granada (Spain) and Eindhoven (Netherlands) (data not
shown), whereas for women with node-positive tumours, sur-
vival ranged from 66% in Ragusa (Italy) and Granada (Spain) to
80% in France (Bas Rhin, Coˆte d’Or, He´rault and Ise`re). Sur-
vival was particularly low for locally advanced (T4) cancers in
Estonia. The high survival for women with distant metastasis in
Granada (Spain) and Mersey (UK) was based only on 9 and 13
cases, respectively. The high 5-year survival in Eindhoven for
TABLE II – 5-YEAR RELATIVE SURVIVAL (%) BY STAGE AND GEOGRAPHIC AREA OF WOMEN DIAGNOSED
WITH BREAST CANCER 1990–1992 FROM SELECTED EUROPEAN REGIONAL GROUPS
Country Regional group
T1
N0
M0
T2–3
N0
M0
T1–3
N
M0
T4
Nx
M0
M1 Notknown Overall
Italy Varese, Firenze, Modena 5-year survival (%) 97.2 92.4 78.7 59.7 22.7 61.1 82.1
Frequency (%) 30.5 19.2 31.4 6.7 5.6 6.6 100
Italy Ragusa 5-year survival (%) 94.9 94.1 65.7 46.6 1.0 75.3 73.9
Frequency (%) 22.1 17.1 34.6 7.8 6.0 12.4 100
France Bas-Rhin, Coˆte d’Or, He´rault, Ise`re 5-year survival (%) 100.0 93.7 80.1 60.5 8.1 72.9 86.0
Frequency (%) 39.4 16.4 31.8 3.4 5.6 3.4 100
France Tarn, Somme, Calvados, Doubs 5-year survival (%) 97.0 86.0 77.2 59.3 13.8 64.8 78.5
Frequency (%) 28.2 17.5 30.4 6.6 5.9 11.4 100
Spain Granada 5-year survival (%) 98.4 81.7 65.8 62.7 46.5 47.2 71.6
Frequency (%) 10.6 26.3 42.5 8.9 5.0 6.7 100
Estonia 5-year survival (%) 97.8 87.8 73.3 23.1 12.0 40.2 66.4
Frequency (%) 8.5 25.0 39.3 12.9 8.0 6.3 100
UK Thames 5-year survival (%) 95.0 88.1 68.2 55.9 25.0 75.8 73.3
Frequency (%) 17.9 14.1 20.9 5.3 10.6 31.2 100
UK Mersey 5-year survival (%) 100.0 76.8 77.0 67.8 45.2 79.9 83.4
Frequency (%) 33.8 22.4 21.5 9.1 5.9 7.3 100
NL Eindhoven 5-year survival (%) 93.7 76.2 74.6 50.7 16.2 92.9 76.0
Frequency (%) 32.4 19.5 31.8 9.2 5.9 1.2 100
All women 5-year survival (%) 97.5 87.0 76.5 54.6 18.4 68.5 79.4
Frequency (%) 28.9 18.6 31.0 6.8 6.2 8.5 100
TABLE I – STAGE, STAGING INVESTIGATIONS, SURGERY AND LOSS TO FOLLOW-UP OF WOMEN DIAGNOSED
WITH BREAST CANCER 1990–1992 FROM SELECTED EUROPEAN GEOGRAPHIC GROUPS
Country Regional group Number of
women
Operated
patients (%)
Axillary
dissection (%)1
10 or more nodes
examined (%)2
% lost to
follow-up
Italy Varese, Firenze, Modena 976 93.1 85.9 77.2 0.8
Italy Ragusa 217 87.5 80.6 71.4 0.0
France Bas-Rhin3, Coˆte d’Or, He´rault3, Ise`re3 865 92.9 89.5 57.5 5.6
France Tarn, Somme, Calvados, Doubs 949 91.1 86.6 60.7 5.3
Spain Granada 179 88.3 79.9 82.5 5.0
Estonia 224 74.5 69.6 3.2 4.9
UK Thames3 340 83.2 50.0 25.9 0.9
UK Mersey3 219 87.6 49.8 18.3 0.0
NL Eindhoven 509 92.7 86.6 51.1 0.0
All cases 4,478 90.2 81.0 58.7 3.0
1Percentage of all women.–2Percentage of women who underwent axillary lymphadenectomy.–3Organized mass screening in place during the
study period.
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women whose disease stage was not speciﬁed (93%, Table II)
was based on only 7 cases.
Table III shows the results of the multiple regression analysis of
relative survival to compare the RER of death between geographic
regions, adjusted for age, stage and the number of lymph nodes
examined during lymphadenectomy. The simplest model (model
1), including only geographic group and age at diagnosis, provided
results closely similar to those from the crude survival analysis.
The RER of death was higher than in northern Italy (the reference
region) in all regions except the French regional group of Bas-
Rhin, Coˆte d’Or, Ise`re and He´rault. In 6 of the 7 regions with a
high RER, the RER of death was statistically signiﬁcant.
Further adjustment for disease stage and surgery was incorpo-
rated in model 2. The 3 components of stage each emerged as
independent prognostic factors, with RER of death strongly and
directly related to tumour size (T), the number of metastatic nodes
(N) and the presence of metastases (M). Surgical treatment proved
to be a signiﬁcant prognostic factor, even after adjustment for
stage. In most regions, the RER of death was lower after adjust-
ment for stage and surgery. Notable exceptions were the French
group of Bas-Rhin, Cote d’Or, He´rault and Ise`re, and Eindhoven
(Netherlands), where the risk increased after this adjustment. In
both these regions, the proportion of women with early stage
disease was higher than in the reference group of northern Italian
registries (see Table II). RERs remained signiﬁcantly higher than
in northern Italy (reference region) in 3 areas: Estonia, Eindhoven
(Netherlands) and the French group of Tarn, Somme, Calvados
and Doubs.
Additional adjustment for the number of axillary nodes exam-
ined was incorporated in the last model (model 3, Table III). With
this adjustment, which characterises better the extent of nodal
involvement, RER of death decreased further in all areas except
Granada (Spain), the only region where more nodes were exam-
ined than in northern Italy (the reference region). RERs associated
with tumour size and metastatic status fell slightly, while the risk
associated with nodal status rose slightly in each node-positive
category. The number of axillary lymph nodes examined also
emerged as an independent prognostic indicator in this model: the
TABLE III – RELATIVE EXCESS RISK (RER) OF DEATH OF WOMEN DIAGNOSED WITH BREAST CANCER
IN 1990–1992 FROM SELECTED EUROPEAN REGIONAL GROUPS
Number of
women
Model 1 Model 2 Model 3
RER RER RER
Country: regional group
Italy: Varese, Firenze, Modena 976 1 1 1
Italy: Ragusa 217 1.71* 1.23 1.21
France: Bas-Rhin, Coˆte d’Or, He´rault, Ise`re 865 0.84 1.12 1.11
France: Tarn, Somme, Calvados, Doubs 949 1.32* 1.35* 1.33*
Spain: Granada 179 1.72* 1.17 1.18
Estonia 224 2.38* 1.55* 1.50*
UK: Thames 340 1.78* 1.24 1.20
UK: Mersey 219 1.08 1.00 0.96
NL: Eindhoven 509 1.45* 1.73* 1.60*
Age (years)
40 296 0.94 1.24 1.24
40–49 797 0.69* 0.82 0.83
50–69 2,155 0.91 1.04 1.04
70 1,230 1 1 1
T stage
T1 1,844 1 1
T2 1,531 2.27* 2.26*
T3 193 3.20* 3.18*
T4 288 3.44* 3.38*
Tx 622 2.95* 2.82*
N stage (no. of metastatic nodes)
0 2,046 1 1
1 478 1.59* 1.63*
2–3 410 2.06* 2.13*
4–5 209 2.87* 2.98*
6–8 172 3.46* 3.65*
9–12 125 4.08* 4.46*
13 139 6.42* 7.46*
Clinically N0 497 2.05* 1.70*
Node-positive, no. of nodes unknown 62 3.21* 2.62*
Nx 340 1.65* 1.37
M stage
M0 4,092 1 1
M 279 3.81* 3.73*
Mx 107 2.22* 2.19*
Surgery
No 438 1 1
Yes 4,040 0.32* 0.33*
Number of axillary nodes examined
Lymphadenectomy not done or not known 1,134 1
1–9 1,215 0.78
10–14 1,120 0.77
15 1,009 0.66*
*Statistically signiﬁcant with p  0.05. Tx, Nx, Mx  T, N and M unknown.
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RER of death fell with increasing numbers of lymph nodes exam-
ined, and was signiﬁcantly lower in patients with 15 or more nodes
examined than in those who did not undergo lymphadenectomy. In
all models, the RER for women aged 40–49 years was lower than
for all other age groups.
All registries were able to provide information on whether
systemic adjuvant radiotherapy, chemotherapy or hormonal ther-
apy was administered. The inclusion of each of these treatment
variables in model 3 did not signiﬁcantly change the overall ﬁt of
the model or the RER of any other variables included in the model.
When no treatment was the reference category, the RER for
chemotherapy was 1.36, that of radiotherapy 0.97 and that of
hormonal therapy (mainly tamoxifen) 0.80, which were not statis-
tically signiﬁcant.
All registries except Eindhoven were able to provide informa-
tion on whether liver and bone scans had been performed in the
staging work-up. Such procedures were frequent in Italy and
France (60–80% of all cases) and much lower in other regions
(20–50%). The inclusion of these variables in the model resulted
in only minor changes in the estimates of RER (data not shown).
We tested several other models to determine the effect of
possible interactions between the variables of model 3; however,
none modiﬁed the pattern of RER by regional group. In particular,
an interaction between stage and the duration of follow-up was
tested to take into account nonproportionality of the risk of death
by time since diagnosis between the various stage categories. This
interaction was statistically signiﬁcant in a model including re-
gional group, age, stage, surgery and the total number of examined
nodes, but it did not change substantially the estimates of RER
(data not shown).
DISCUSSION
Our analysis shows that the marked differences in survival for
breast cancer across Europe, for patients diagnosed in 1990–1991,
are mainly due to differences in cancer stage at diagnosis. After
adjustment for stage and for the number of axillary nodes exam-
ined, as a confounder of staging, survival differences between
registries and regions were greatly reduced. However, in 3 of the
9 regional groups, RERs of death remained signiﬁcantly high even
after these adjustments.
Overall 5-year relative survival in Estonia and the 8 regional
groups in 5 other countries ranged from 66% to 86%. Geographic
variation in stage-speciﬁc survival differed notably between early
and advanced stage disease. For very early stage disease
(T1N0M0), regional differences were small: these tumours are
relatively unlikely to have nodal involvement and occult metasta-
ses, so whether the work-up is intense or cursory, the result will
usually be no nodes or metastases (N0M0). By contrast, the wider
regional variation in survival for larger node-negative tumours
(T2-3N0M0) may be partly explained by the fact that these tu-
mours have a greater intrinsic probability of regional or distant
spread at the time of diagnosis,11 so the accuracy of staging in
patients categorised as (N0M0) will be much more sensitive to the
intensity of the work-up. In areas where clinicians do not perform
an extensive work-up, many larger tumours categorised as node-
negative and free of metastases (T2-3N0M0) may in fact have
occult regional or distant spread, while in a region where a more
intensive work-up is performed, a greater proportion of these
tumours will be truly node-negative and free of metastases.
The probability of ﬁnding nodal and distant metastases depends
on the diagnostic examinations performed, which in turn depend
both on the attitudes and training of the clinicians, and on the
availability of appropriate equipment and techniques. The latter
will be closely related to the overall afﬂuence of a region.
The number of positive nodes was strongly correlated with the
number of nodes examined (r  0.74). UK registries and Estonia,
however, which had the highest percentage of cases with patho-
logic conﬁrmation of lymph node spread (pN), had the lowest
mean number of nodes examined. This suggests that, in these
countries, the axillary nodes tend to be examined pathologically
only when there is a prior clinical suspicion of nodal involvement,
rather than as a routine procedure.
In the multiple regression analysis, adjusting for age (model 1)
did not substantially change the relative survival pattern. After the
inclusion of stage and surgery, the RER of death in most regions
moved towards 1, indicating that stage at diagnosis was a key
determinant of regional differences in survival. A further move-
ment of RER towards 1 occurred after adjustment for the number
of lymph nodes examined. This procedure improves the adjust-
ment of disease stage in the analysis, because the chance that
advanced cases may be misclassiﬁed to a less advanced category
will be expected to fall as the number of nodes examined increases.
Thus, when the number of examined nodes is large, cases classi-
ﬁed as node-negative are unlikely to be false negatives, and node-
positive cases will include some cases with only minor nodal
involvement. The improved adjustment for stage is reﬂected by a
slight increase in the risk of death for each node-positive category,
and a low risk for cases with 15 or more nodes examined. In
regions where the number of axillary nodes examined was lower
than in the reference region, the RER generally fell after adjust-
ment for the number of nodes examined, which suggests that the
number of nodes examined should be included in future survival
comparisons.
Further adjustments will be necessary in the future to take into
account the increasing use of sentinel node sampling.
Patients treated surgically had a signiﬁcantly lower RER than
those not operated on for the same stage and other therapy cate-
gory (radio-, chemo- and hormono-therapy). We expected the
prognostic signiﬁcance of surgery to decrease when these addi-
tional therapies were taken into account (i.e., the RER of surgery
should have increased). However, although use of radiotherapy
and tamoxifen were associated with a more favourable prognosis,
the RER for surgery was not affected by the inclusion of these
additional therapies in the multivariable regression model. Practi-
cally all patients not treated surgically (10% of total cases) had
either advanced or unknown stage tumours, and we propose they
were probably considered unlikely to beneﬁt from surgery. Ac-
cording to this interpretation, surgery is a proxy of stage.
We emphasise that only information on whether or not radio-,
chemo- and hormono-therapy was performed was available in our
study, with no details as to type and dose schedule. It is possible
that a favourable prognostic effect of such therapy would be
revealed by a more detailed analysis that also considered type and
dose.
Women aged 40–49 at diagnosis had the best prognosis of all
age groups, as found in other studies.1,14–16 The persistence of this
phenomenon after careful adjustment for stage suggests that it is a
biologic phenomenon not simply related to earlier diagnosis.
Adjustment for stage and the number of axillary nodes exam-
ined greatly reduced the geographic variation in excess risk. The
excess risks for Thames and Mersey (UK) decreased markedly
with this adjustment, strongly suggesting that a major reason for
the comparatively low survival of breast cancer patients in En-
gland, highlighted by the EUROCARE study during the 1980s,
was more advanced stage at diagnosis. The results for Thames,
however, should be regarded with caution because of the high
number cases with unknown stage. The high percentage of cases
with unknown stage in this registry has been investigated,17 and
was found to be due to missing information in hospital clinical
records.
In 3 regions (Estonia, Eindhoven and the France registries of
Tarn, Somme, Calvados and Doubs), the RER of death remained
signiﬁcantly higher than in Northern Italy (reference region). The
RER of death fell in Estonia after stage adjustment, but later stage
at presentation did not completely explain the excess, indicating
that the management of breast cancer patients is not optimal in
Estonia. This is consistent with the low survival for most cancers
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in Estonia in relation to low socioeconomic level.18–21 Although
5-year survival of locally advanced and metastatic cases in Estonia
was especially low, cases diagnosed at an early stage had fairly
good survival.
Overall and stage-speciﬁc 5-year relative survival in Eindhoven
was lower than the average for the study population, and signiﬁ-
cantly lower than in northern Italy (reference group). The RER of
death in Eindhoven increased after adjustment for stage (model 2)
because stage distribution was apparently more favourable, but
decreased after adjustment for number of nodes examined (model
3) because, on average, fewer nodes were examined than in the
reference region. These ﬁndings suggest that the low overall and
stage-speciﬁc survival in Eindhoven might be due to less than
optimal patient management after diagnosis, although the available
information indicated fairly good adherence to protocols;22–24 a
different distribution of tumour biology cannot be excluded.25
Only 40% of women over 50 in Eindhoven received tamoxifen as
adjuvant therapy, less than the average for the whole study popu-
lation, but similar to that in the reference region.3 Women in
Eindhoven had a higher proportion of early stage cancers
(T1N0M0 and T2-3N0M0) than in most regions, but with lower
stage-speciﬁc survival rates than in all the other regional groups,
which may indicate some underestimation of the extent of the
disease. This is supported by the fact that the average number of
lymph nodes examined in Eindhoven was also low, and the RER
of death decreased substantially after adjustment for this variable.
Further, among small tumours (pT1, less than 2cm), the percentage
of very small tumours (pT1a, less than 0.5 cm) in Eindhoven was
lower (2.3%) than in France (6.0%) or Italy (3.3%).
The RER of death in the French group of Tarn, Somme, Cal-
vados and Doubs was higher than in northern Italy (reference) and
the other French group of Bas-Rhin, Coˆte d’Or, He´rault and Ise`re.
The registries of Somme and Doubs had the highest percentage of
cases of unknown stage in this group. The survival of cases for
which information on stage is not available may not be represen-
tative of the survival of all cases, and this could bias stage-adjusted
survival comparisons if such cases constitute a high proportion of
the total. When we excluded Somme and Doubs from the analysis,
the differences in RER between the 2 French groups narrowed.
In Ragusa (Italy) and Granada (Spain), 2 regions with relatively
low socioeconomic level, survival was low for several TNM
categories, suggesting that the availability of appropriate diagnos-
tic and treatment modalities was far from optimal.26
Breast cancer screening was introduced during the early 1990s
in many European countries.13 Screening is usually offered to
women aged 50 and over (50–64 in UK, 50–64 or 50–69 in
France in the study period). The implementation of a screening
programme, however, may inﬂuence the proportion of tumours
diagnosed at an earlier stage at any age, because population screen-
ing requires the establishment of appropriate structures for diag-
nosis and treatment that beneﬁt the entire population. Adjustment
for stage, however, is expected to take into account the effect of
lead time that can arise as a result of both mass (organised) and
opportunistic screening. For the French registries of Bas-Rhin,
He´rault and Ise`re, and both UK registries, mass screening activity
had begun in the territories they cover at the end of the 1980s,
before the period of diagnosis covered by our study. One might
expect, therefore, that patients diagnosed in the study period in
these areas would include a higher proportion with slow-growing
tumours that would later have been diagnosed clinically if not
detected at the ﬁrst round of screening (length-biased sampling). In
the UK, however, the ﬁrst round of screening was not terminated
until well after 1991, particularly in some Thames areas, suggest-
ing that this bias is unlikely to be major. In the French registries
where screening was in force, the incidence of breast cancer was
stable from 1989 to 1991,27 suggesting that the effect of screening
on the detection of slow-growing cancers was already over when
the cases were sampled for our study (1990 incidence).
Any screening effect on survival should be conﬁned to (or more
marked for) women diagnosed in the age range 50–64 years. To
explore this potential bias, we examined the RER of death sepa-
rately for women aged under 50, 50–64 and 65 or more, adjusting
for stage, surgery and the number of examined nodes (see Table
IV). In the French regional group where screening was in place
(Bas-Rhin, He´rault and Ise`re), the stage-adjusted RER was actu-
ally higher for women offered screening (aged 50–64 years) than
for younger or older women (Table IV). In both UK regions, the
RER for women aged 50–64 was intermediate between that for
younger and older women. These results do not support the argu-
ment that screening activity inﬂuenced the stage-adjusted compar-
ison of survival between regions. The low RER for women aged
under 50 is also be related to the good prognosis of women aged
40–49.
It is noteworthy that full adjustment for stage completely ex-
plained the excess death risk for the oldest patients in the UK, seen
for women diagnosed during 1978–1985.1 This more favourable
stage-adjusted prognosis may be related to the wide use of tamox-
ifen in the UK.3 In Eindhoven, on the contrary, where tamoxifen
was less widely used, the highest RER was found in the oldest age
group.
In order to reduce geographic differences in breast cancer survival,
and to bring regions with poorer survival up to those with the best, the
most important public health intervention would be to ensure that
health services have adequate facilities for prompt diagnosis of dis-
ease, and that all citizens have equal access to those facilities. For
many populations, this conclusion likely remains valid today. Persis-
tent geographic differences in the risk of death, despite careful ad-
justment for the stage of disease at diagnosis, suggests that some
European regions provided less than optimal treatment for breast
cancer patients. Since the early 1990s, however, methods of diagnosis
and treatment of breast cancer have changed markedly, and adherence
to protocols has improved. Further studies will be needed to monitor
the impact of these changes on survival and the probability of curing
breast cancer patients.
TABLE IV – RELATIVE EXCESS RISK (RER) OF DEATH BY AGE AT DIAGNOSIS OF WOMEN DIAGNOSED WITH BREAST CANCER
IN 1990–1992 FROM SELECTED EUROPEAN REGIONAL GROUPS
Country Regional group
Under 50 years 50–64 years 65–99 years
Number of
women
RER Number of
women
RER Number of
women
RER
Italy Varese, Firenze, Modena 222 1 333 1 421 1
Italy Ragusa 48 1.86 76 2.231 93 0.70
France Bas-Rhin, Coˆte d’Or, He´rault, Ise`re 203 0.98 294 1.43 368 1.01
France Tarn, Somme, Calvados, Doubs 233 1.50 346 1.741 370 1.11
Spain Granada 58 0.79 61 2.32 60 0.75
Estonia 61 1.15 80 2.531 83 1.18
UK Thames 85 1.86 126 1.721 129 0.88
UK Mersey 42 1.68 87 1.21 90 0.63
NL Eindhoven 141 1.36 170 1.64 198 2.021
Risks are adjusted for region, age, stage and staging investigations, surgery (see Table 3). –1Statistically signiﬁcant with p  0.05.
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